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H ead and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer 
globally,  and the prognosis of HNSCC remains poor,  
since the disease is locally advanced at diagnosis in 
more than 60% of patients [1].  The prognosis is espe-
cially poor and the treatment choices are particularly 
limited for patients with recurrent disease or distant 
metastases [2].  Although cetuximab,  a monoclonal 
antibody targeting the epidermal growth factor receptor 
(EGFR),  and platinum-based chemotherapy are the 
standard treatments for recurrent/metastatic (R/M) 
HNSCC [3],  the treatment efficacy must be improved 
and the treatment-related toxicity decreased.  Immuno-
therapeutic approaches are continually being developed 
and improved in the field of oncology.  A prominent 
example is nivolumab,  an anti-programmed cell death 
protein-1 (PD-1) monoclonal antibody,  which achieved 
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Recurrent or metastatic head and neck squamous cell carcinoma (R/MHNSCC) has a poor prognosis.  Although 
nivolumab is approved in Japan for treating R/MHNSCC,  the response rate is low.  Therefore,  identifying pre-
treatment prognostic factors is necessary.  This study assessed the utility of the neutrophil-to-lymphocyte ratio 
(NLR) and Glasgow Prognostic Score (GPS) as biomarkers of response to nivolumab.  We retrospectively col-
lected the data of 56 R/MHNSCC patients treated with nivolumab between May 2017 and December 2019.  The 
Kaplan–Meier method and log-rank test were used to estimate overall survival (OS) and progression-free sur-
vival (PFS),  and multivariate Cox hazard regression analysis was used to identify independent predictors of 
survival.  Patients with a low pretreatment NLR had prolonged OS,  and patients with a low pretreatment GPS 
had increased OS and PFS.  A performance score (PS) of 0-1,  development of immune-related adverse events,  
and GPS of 0-1 were significantly associated with OS in multivariate analysis.  In summary,  baseline pretreat-
ment NLR and GPS are independently associated with OS in R/MHNSCC patients treated with nivolumab.  
Administration of nivolumab while maintaining the PS reflects a immune status of the host and leads to a good 
OS.
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an improvement in overall survival (OS) compared with 
standard therapy (cetuximab,  methotrexate,  or 
docetaxel) for patients with platinum-refractory R/M 
HNSCC in the CheckMate 141 trial [4].  Based on these 
results,  the authors of the CheckMate 141 trial con-
cluded that nivolumab should be considered the stan-
dard subsequent-line treatment for R/MHNSCC [5].  
Unfortunately,  despite the initial expectations,  it has 
become increasingly clear that only a minority of R/
MHNSCC patients derive benefit from nivolumab in 
clinical practice.  There is thus a critical need to identify 
novel biomarkers to predict the nivolumab response.
For this reason,  a significant amount of research in 
HNSCC has been devoted to clarifying the tumor 
PDL-1 expression,  tumor mutational burden,  interfer-
on-γ signature,  tumor microenvironment,  etc.  [6].  
Although these researches are often helpful,  such 
approaches are not feasible for some patients due to the 
limited availability,  amount,  and condition of pre-
served tumor tissues.  To overcome the need for tissue 
samples,  efforts have been directed toward readily 
accessible samples such as peripheral blood.  In recent 
researches,  peripheral blood-based parameters (PBBPs),  
such as C-reactive protein (CRP),  albumin (Alb),  
absolute neutrophil count (ANC),  absolute lymphocyte 
count (ALC),  neutrophil-to-lymphocyte ratio (NLR),  
and platelet-to-lymphocyte ratio (PLR),  have been 
reported as prognostic indicators for the efficacy of 
immunotherapy in various cancers [7-9].  Pretreatment 
NLR and PLR have shown particular promise as cheap 
and readily available biomarkers in melanoma,  lung 
carcinoma and renal cell carcinoma [7,10-12].  However,  
the utility of PBPPs has not been studied in HNSCC.
This study aimed to evaluate whether PBBPs could 
have predictive value in R/MHNSCC patients treated 
with nivolumab.
Materials and Methods
Patients. This retrospective cohort study was 
conducted at the Hiroshima University Hospital in 
Japan between May 2017 and December 2019.  
Eligibility criteria for inclusion in this study were the 
presence of pathologically confirmed HNSCC,  age of 
≥ 18 years,  and an Eastern Cooperative Oncology 
Group performance status (ECOG PS) score of 0-2 at 
the initiation of nivolumab treatment.  Patients who had 
previously received immunotherapeutic agents were 
excluded from the analysis.  Nivolumab was adminis-
tered at a dose of 240 mg/kg body weight every 2 weeks.
The Institutional Review Board of Hiroshima 
University Hospital approved this study (Hiroshima 
University Hospital IRB E-1324).
Data collection. We retrospectively collected the 
following clinical data for all patients: age,  sex,  body 
mass index (BMI),  smoking history,  primary tumor 
location,  tumor-node-metastasis (TNM) stage,  previ-
ous treatments,  immune-related adverse events (irAEs),  
CRP,  Alb,  ALC,  NLR,  PLR,  tumor response,  out-
comes,  and ECOG PS,  of R/MHNSCC patients in elec-
tronic medical databases.  BMI was categorized as either 
underweight (BMI < 18.5 kg/m2),  normal weight (18.5  
kg/m2 < BMI < 25.0 kg/m2) or above (BMI ≥ 25.0 kg/m2) 
according to standard World Health Organization defi-
nitions.  The NLR was calculated as the ratio of ANC to 
ALC,  and the PLR was calculated as the ratio of PLT to 
ALC.  The ALC,  NLR,  and PLR at immunotherapy 
initiation were considered as the baseline values.  
Baseline blood cell counts were categorized according to 
the upper (ANC) or lower (ALC) limits of normal.  The 
Glasgow Prognostic Score (GPS) has been reported to 
reflect systemic inflammatory conditions and malnutri-
tion due to cancer [13].  The GPS classification was cal-
culated using CRP and Alb based on the cutoff values 
from previous reports [14] — namely,  a CRP cutoff of 
1.0 mg/dL and an Alb cutoff of 3.5 g/dL.  TNM classifi-
cation was determined using the 8th edition of the 
Union for International Cancer Control staging system.  
Tumor response was evaluated according to the Response 
Evaluation Criteria in Solid Tumors (RECIST),  version 
1.1.  The imaging interval for assessment was 8 to 12 
weeks for most patients.
The primary outcome was OS,  defined as the num-
ber of months between the first nivolumab treatment 
and death or the date of last patient contact.  The sec-
ondary outcome was PFS,  which was defined as the 
number of months between the first nivolumab treat-
ment and death or progression.
Statistical analysis. Statistical analyses were per-
formed using JMP pro version 14.0 (developed by the 
SAS Institute).  Continuous variables are reported as the 
median (range) and categorical variables are reported as 
the proportion and/or percentage.  The Kaplan–Meier 
method and log-rank test were used to estimate and 
compare OS and PFS rates.  We obtained hazard ratios 
(HRs) using a Cox proportional hazards model.  Factors 
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significantly associated with response to nivolumab 
were analyzed using a Cox regression analysis.  We per-
formed multivariate Cox hazard regression analysis on 
variables that showed significance in the univariate 
analysis.  HRs and corresponding 95% confidence inter-
vals (CIs) were reported.
To evaluate the ability of the ALC,  NLR,  and PLR to 
predict survival,  receiver operating characteristic 
(ROC) curve analysis with the Delong method was used 
to determine the area under the curve (AUC).
Results
Patients characteristics. The number of recruited 
patients was 56 and their characteristics are listed in 
Table 1.  The majority of patients were male,  had a his-
tory of smoking,  BMI ≥ 18.5,  ECOG PS of 0-1,  Stage 
IV,  and pharynx cancer.  More than half of patients had 
previously received lines of systemic cancer therapy for 
metastasis (60.7%) and had previously received cetux-
imab (58.9%).  The median baseline ALC,  NLR,  and 
PLR were 1,025/µL,  5.16 and 275.2,  respectively.  GPS0/1 
patients accounted for 67% of the total population 
(Table 1).
Survival outcomes. For the whole group analysis,  
the median observation period,  median OS,  and median 
PFS were 19.5 months,  9.0 months (95%CI 7-12),  and 
5.0 months (95%CI 2-9),  respectively (Fig. 1).  The 
overall response rate (ORR) was 32.1% (18 of 56 
patients).  The median time to response was 2.59 
months.
Immuno-related adverse events. 15 (26.7%) 
patients experienced irAEs and the most common irAE 
was liver dysfunction.  Only one patient developed 
severe diarrhea (Grade 3); this patient was treated with 
systemic corticosteroids (Table 2).
Prognostic factors. The details of the analysis of 
factors prognostic for survival are shown in Tables 3 
and 4.  The CDDP-resistant group had significantly 
worse prognosis compared with the other groups 
(Fig. 2).  CDDP intolerance group was defined as an 
inability to receive adequate administration of CDDP 
for any of several reasons: a performance status of 
ECOG 3 or higher,  organ dysfunction of grade 2 or 
higher based on the NCI CTCAE (National Cancer 
Institute Common Toxicity Criteria for Adverse Events),  
such as hearing loss,  tinnitus,  neurologic disorders,  
prolonged bone-marrow suppression,  hypersensitivity 
to platinum,  and renal dysfunction (creatinine clear-
ance of < 50 ml/min).
Cutoff values of NLR,  PLR,  and MLR as analyzed 
by the receiver operating characteristic (ROC) curve 
were 5.2 (AUC: 0.6834),  0.46 (AUC: 0.6377) and 238 
(AUC: 0.6531),  respectively (Fig. 3).
In the univariate analysis for OS,  NLR (p = 0.039),  
PLR (p = 0.011),  PS p = 0.0002),  developing irAEs 
(p = 0.03),  and GPS (p = 0.005) showed statistical signif-
icance.  PS (p = 0.011) and developing irAEs (p = 0.061) 
also showed significance in the multivariate analysis 
(Fig. 4).
Finally,  the univariate analyses also indicated that PS 
(p = 0.011),  BMI (p = 0.036),  PLR (p = 0.047),  and GPS 
(p = 0.015) were significantly associated with PFS,  while 
none of these factors was found to be significant in the 
multivariate analysis.
Discussion
Over the past several years,  immune checkpoint 
inhibitors (ICIs),  which target inhibitory receptors on T 
cells and reinvigorate immune responses,  have begun to 
transform clinical cancer treatment strategies,  and the 
recent approval of several blockers of the cytotoxic 
T-lymphocyte–associated antigen 4 (CTLA-4) and the 
PD-1/PD-L1/PD-L2 pathway have ushered in an era of 
ICI therapy.  Checkpoint blockers can induce good anti-
tumor response and survival advantage in patients with 
advanced melanoma,  NSCLC,  renal cancer,  gastric 
cancer,  and head and neck cancer,  among others.  
However,  most patients show only a limited or tran-
sient response.  Therefore,  intense research is underway 
to identify and develop biomarkers predictive of ICI 
response.
Biomarkers are indicators of a particular disease 
state or some other physiological state of an organism,  
and they are classified in accordance with their purpose,  
which could be early diagnosis,  prospective prognosis,  
or prediction of treatment response.  Regarding predic-
tive biomarkers for ICIs,  numerous studies have focused 
on the status of the tumor microenvironment,  such as 
PD-L1 expression,  tumor-infiltrating lymphocytes,  
T-cell receptor clonality,  mutational or neoantigen bur-
den,  immune gene signatures,  and multiplex immuno-
histochemistry as potentially beneficial predictors [15].  
However,  the evaluation of these aspects of the tumor 
microenvironments has some limitations.  Sometimes,  
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Age Median (range) ― years 66 (31-90)
≧75 years ― no. (％) 11 (19.6)
≥65 years ― no. (%) 29 (51.7)
<65 ― no. (%) 27 (48.2)
Male　― no. (%) 40 (71.4)
Smoking ― no. (％) 40 (71.4)
BMI (kg/m2) ― no. (%)
<18.5 23 (41.1)
18.5≦ 33 (58.9)











Site of primary tumor ― no. (％)
Larynx 3 (5.4)
Oral cavity 17 (30.4)
Pharynx 34 (60.6)
Others 2 (3.6)





Recurrent site ― no. (％)
Primary site 20 (35.7)
Neck 14 (25.0)
Distant 22 (39.2)
Previous receipt of cetuximab ― no. (％) 33 (58.9)












BMI,  body mass index; ECOG PS,  Eastern Cooperative Oncology Group performance score; UICC,  union for international cancer con-
trol; TNM,  tumor-node-metastasis; CDDP,  cisplatin; ALC,  absolute lymphocyte count; AMC,  absolute monocyte count; NLR,  neutrophil 
to lymphocyte ration; MLR,  monocyte to lymphocyte ratio; PLR,  platelet to lymphocyte ratio; CRP,  C-reactive protein; Alb,  Albumin.
invasive procedures are required to obtain fresh tumor 
cells,  such as open biopsy,  core-needle biopsy,  or lung 
tissue biopsy with computed tomographic guidance.  
Additionally,  individual biomarkers can vary in 
appearance depending on the state of tissue preserva-
tion,  the part of the tumor tissue,  the selection of 
immunohistochemical antibody agents,  and time-de-
pendent changes.  For all these reasons,  immunohisto-
chemical biomarkers have low reliability and are not 
considered conclusive.
Peripheral blood markers are a noninvasive source of 
potential biomarkers in patients receiving ICI therapies.  
Because both CTLA-4 and PD-1 are expressed mainly 
on lymphocytes,  several reports have pointed to the 
association between the blood lymphocyte count and 
tumor response to ICI [16-18].  Martens et al.  showed 
that high levels of relative lymphocyte counts at baseline 
were significantly associated with longer OS in patients 
with melanoma.  In another study,  Nakamura et al.  
showed that absolute lymphocyte counts of 3 and 6 
(× 103/μL) after the initial administration of nivolumab 
were significantly correlated with better OS in patients 
with melanoma.  These results suggest that lymphocyte 
counts,  both at baseline and after treatment with ICI,  
may be useful for predicting better outcomes.
Neutrophils have been shown to play a critical role in 
the production of cytokines that drive neoangiogenesis 
and of chemical ligands that induce an increase of 
tumor cells.  Therefore,  an increase of neutrophils can 
be viewed as a promotion of tumor increase and metas-
tasis.  However,  a decrease of lymphocytes can repre-
sent an insult to the host immune mechanism,  leading 
to a dismal prognosis.  The utility of NLR lies in its 
reflection of the balance between a tumor promotion 
and an antitumor immune state.  In other words,  the 
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Table 2　 Response to nivolumab and immune-related adverse 
events




Time to response (TTR),  months 2.59









CR,  complete response; PR,  partial response; SD,  stable disease;  































































Fig. 2　 Comparison of overall survival (OS) between CDDP resis-
tance group and CDDP intolerance group.
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Table 3　 Univariate and multivariate analyses for factors associated with overall survival
Univariate analysis Multivariate analysis
Characteristic Reference HR (95%CI) p-value HR (95％CI) p-value
Age ≧65 years <65 years 0.894 (0.480-1.665) 0.724
Sex Male Female 1.738 (0.884-3.419) 0.109
Smoking Smoker non-smoker 0.988 (0.501-1.948) 0.972
PS 0-1 ≧2 0.197 (0.082-0.468) 0.0002 0.279 (0.104-0.748) 0.011
Stage Ⅰ-Ⅱ Ⅲ-Ⅳ 1.270 (0.602-2.679) 0.529
Number of prior therapies ≧2 <2 0.773 (0.339-1.761) 0.541
Cetuximab Yes No 1.00 (0.523-1.919) 0.995
IrAE Yes No 0.445 (0.214-0.926) 0.03 0.469 (0.213-1.035) 0.061
BMI <18.5 ≧18.5 1.704 (0.913-3.178) 0.094
ALC ≧900 <900 1.127 (0.599-2.119) 0.709
NLR <5.2 ≧5.2 0.515 (0.274-0.968) 0.039 0.731 (0.298-1.794) 0.495
MLR <0.46 ≧0.46 0.823 (0.439-1.544) 0.544
PLR <238 >238 0.449 (0.225-0.878) 0.019 0.918 (0.341-2.470) 0.866
GPS 0-1 2 0.382 (0.195-0.748) 0.005 0.491 (0.204-1.182) 0.112
HR,  hazard ratio; CI,  confidence interval; irAE,  immune-related adverse event; BMI,  body mass index; ALC,  absolute lymphocyte 
count; NLR,  neutrophil to lymphocyte ratio; MLR,  monocyte to lymphocyte ratio; PLR,  platelet to lymphocyte ratio; GPS,  Glasgow 
Prognostic Score.
Table 4　 Univariate and multivariate analyses for factors associated with progression-free survival
Univariate analysis Multivariate analysis
Characteristic Reference HR (95%CI) p-value HR (95％CI) p-value
Age ≧65 years <65 years 0.785 (0.428-1.441) 0.435
Sex Male Female 0.62 (0.318-1.210) 0.161
Smoking Smoker non-smoker 1.028 (0.525-2.010) 0.937
PS 0-1 ≧2 0.346 (0.153-0.785) 0.011 0.452 (0.191-1.07) 0.072
Stage Ⅰ-Ⅱ Ⅲ-Ⅳ 1.165 (0.556-2.443) 0.685
Number of prior therapies ≧2 <2 0.708 (0.312-1.603) 0.407
Cetuximab Yes No 1.006 (0.538-1.881) 0.984
IrAE Yes No 0.534 (0.260-1.094) 0.087
BMI <18.5 ≧18.5 1.924 (1.043-3.549) 0.036 1.602 (0.850-3.020) 0.145
ALC ≧900 <900 1.287 (0.692-2.392) 0.425
NLR <5.2 ≧5.2 0.686 (0.372-1.264) 0.227
MLR <0.46 ≧0.46 1.023 (0.551-1.898) 0.942
PLR <238 >238 0.561 (0.292-1.077) 0.082
GPS 0-1 2 0.438 (0.227-0.846) 0.014 0.591 (0.293-1.192) 0.142
HR,  hazard ratio; CI,  confidence interval; irAE,  immune-related adverse event; BMI,  body mass index; ALC,  absolute lymphocyte 
count; NLR,  neutrophil to lymphocyte ratio; MLR,  monocyte to lymphocyte ratio; PLR,  platelet to lymphocyte ratio; GPS,  Glasgow 
Prognostic Score.
NLR can represent immunocompetence.  Our previous 
study found that a baseline NLR < 5 and PS of 0 were 
associated with increased OS and clinical benefit in 
patients with R/MHNSCC treated with nivolumab [19].  
In this study,  we revealed the significant associations 
between the prognosis of patients treated with 
nivolumab and each of NLR,  PLR,  PS,  and GPS and 
the development of irAEs.  The patients with a good 
prognosis had a tendency to exhibit decreased NLR and 
a slight change of the value.
As is true of neutrophils,  blood platelets are one of 
the typical blood cell components driving the inflam-
matory response,  and thrombocytosis often appears in 
solid tumors with chronic inflammation.  Because blood 
platelets are deeply involved in tumor cell progression,  
it seems reasonable to infer that PLR may be an effective 
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Fig. 4　 A,  Comparison of overall survival and progression free survival with cutoff value of NLR; B,  Comparison of overall survival and 
progression free survival with cutoff value of GPS.
NLR,  neutrophil to lymphocyte ration; GPS,  Glasgow prognostic Score.
prognosis prediction marker.
Previous studies have demonstrated that the host 
inflammatory response is a vital determinant of disease 
progression [20-22].  To evaluate the systemic inflam-
matory response,  Forrest et al.  introduced the Glasgow 
Prognostic Score (GPS),  which combines the pretreat-
ment albumin and C-reaction protein (CRP) levels,  and 
showed that it was an independent predictor of OS in 
patients with NSCLC [23].  In 2007,  McMillan et al.  
[24] suggested a modified GPS (mGPS) to evaluate the 
prognostic effect on patients with rectal and colon can-
cers,  which could provide additional prognostic infor-
mation for clinical practice.  Recently,  the prognostic 
role of GPS/mGPS was proved in various cancer types,  
and GPS/mGPS was introduced as a potential prognos-
tic test for the response to immunotherapy [25-27].  In 
other words,  a low GPS score represents good nutri-
tional status and sufficient tumor immunity.
It has been reported that the incidence of irAEs cor-
relates with the efficacy of nivolumab in patients with 
NSCLC or advanced melanoma [28 , 29].  In this study,  
the rate of irAEs of any grade was similar to that 
reported in the CheckMate 141 trial.  Although the 
exact mechanisms causing these adverse events are 
unknown,  it is likely that inhibiting immune check-
points affects the maintenance of immune homeostasis,  
allowing T cells to react with self-antigens,  and that 
different checkpoint inhibitors will have distinct 
immune toxicity profiles [30].
Our results indicate that nivolumab treatment is 
more effective when the patient is in a good general 
condition and that PBBPs are convenient markers for 
patient outcome.  Although a comparison between 
CDDP responses showed that the CDDP-resistant 
group had a significantly worse prognosis,  treatment 
history with cetuximab showed no remarkable associa-
tion.  However,  the results of this study should be inter-
preted with care.  Several limitations must be consid-
ered,  including the small sample size,  retrospective 
nature,  and single-center design of this study.  Larger 
cohorts and longer follow-up periods will be needed to 
validate these findings.
In conclusion,  This study demonstrates that baseline 
pretreatment NLR and GPS are independently associ-
ated with OS in patients with R/MHNSCC treated with 
nivolumab.  Administration of nivolumab while main-
taining PS reflects a immune status of the host and leads 
to a good OS.  Further studies are needed to determine 
the value of NLR in the context of other biomarkers for 
ICI therapy.
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